These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 19016764)

  • 1. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients.
    Shim JH; Park JW; Kim JH; An M; Kong SY; Nam BH; Choi JI; Kim HB; Lee WJ; Kim CM
    Cancer Sci; 2008 Oct; 99(10):2037-44. PubMed ID: 19016764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level.
    Li X; Feng GS; Zheng CS; Zhuo CK; Liu X
    World J Gastroenterol; 2004 Oct; 10(19):2878-82. PubMed ID: 15334691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.
    Hsieh MY; Lin ZY; Chuang WL
    Kaohsiung J Med Sci; 2011 Aug; 27(8):314-22. PubMed ID: 21802642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
    Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
    Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients.
    Ranieri G; Ammendola M; Marech I; Laterza A; Abbate I; Oakley C; Vacca A; Sacco R; Gadaleta CD
    World J Gastroenterol; 2015 May; 21(19):6018-25. PubMed ID: 26019468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relation between vascular endothelial growth factor and reoccurence-metastasis after transcatheter arterial chemoembolization in hepatocellar carcinoma].
    Xiong ZP; Yang SR; Xiao EH; Zhou SK; Zhang ZS; Liang ZY
    Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):562-5. PubMed ID: 14690562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.
    Sergio A; Cristofori C; Cardin R; Pivetta G; Ragazzi R; Baldan A; Girardi L; Cillo U; Burra P; Giacomin A; Farinati F
    Am J Gastroenterol; 2008 Apr; 103(4):914-21. PubMed ID: 18177453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Xiong ZP; Yang SR; Liang ZY; Xiao EH; Yu XP; Zhou SK; Zhang ZS
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):386-90. PubMed ID: 15313674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of endostar combined with transcatheter arterial chemoembolization and analysis of vascular endothelial factor and C-reactive protein levels in patients with advanced hepatocellular carcinoma under contrast enhanced ultrasound.
    Wang Y; Xuan Z; Zheng X; Han R; Zhou L; Liu H; Liu Y
    J BUON; 2019; 24(6):2394-2401. PubMed ID: 31983111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients.
    Farid K; Elalfy H; Abo El-Khair SM; Elgamal H; Besheer T; Elmokadem A; Shabana W; Abed S; Elegezy M; El-Khalek AA; El-Morsy A; Negm A; Elsamanoudy AZ; El Deek B; Amer T; El-Bendary M
    Expert Rev Gastroenterol Hepatol; 2020 Dec; 14(12):1203-1214. PubMed ID: 32933325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between the changes of VEGF level and dendritic cells in peripheral blood of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Liu J; Yi J
    J Huazhong Univ Sci Technolog Med Sci; 2007 Feb; 27(1):58-60. PubMed ID: 17393111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
    Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
    Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
    He K; Yang Z; Liu X; Yang Y; Song W; Wang S; Chen Y
    Curr Oncol; 2022 Dec; 30(1):476-491. PubMed ID: 36661687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study.
    Poon RT; Lau C; Yu WC; Fan ST; Wong J
    Oncol Rep; 2004 May; 11(5):1077-84. PubMed ID: 15069550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of doxorubicin on the changes of serum vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization (TACE).
    Leelawat K; Laisupasin P; Kiatdilokrut A; Pongtongpool T; Narong S; Samkhumphim N; Ket-Horm S
    J Med Assoc Thai; 2008 Oct; 91(10):1539-43. PubMed ID: 18972897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization.
    Wu YQ; Fan WZ; Xue M; Guo J; Wei JL; Wang Y; Yao W; Zhao Y; Li JP
    Clin Transl Oncol; 2020 Jan; 22(1):70-80. PubMed ID: 31183764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
    Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIF-1α and VEGF as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization.
    Pinto E; Pelizzaro F; Cardin R; Battistel M; Palano G; Bertellini F; Kitenge MP; Peserico G; Farinati F; Russo FP
    Dig Liver Dis; 2024 May; 56(5):872-879. PubMed ID: 37783655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between insulin-like growth factor-2 expression and prognosis after transcatheter arterial chemoembolization and octreotide in patients with hepatocellular carcinoma.
    Xiong ZP; Huang F; Lu MH
    Asian Pac J Cancer Prev; 2012; 13(7):3191-4. PubMed ID: 22994732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study.
    Lee HS; Kim KM; Yoon JH; Lee TR; Suh KS; Lee KU; Chung JW; Park JH; Kim CY
    J Clin Oncol; 2002 Nov; 20(22):4459-65. PubMed ID: 12431969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.